ClinicalTrials.gg
Active, not recruitingNCT05925530MDT-BRIDGEUpdated Sep 9, 2026

Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)

A Phase 2 interventional study of Durvalumab in Non-small Cell Lung Cancer, sponsored by AstraZeneca. Active, not recruiting at 49 sites in 11 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
142
Allocation
Not applicable
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung — 16 open to participants now, 37 under way, 11 of them phase 3. durvalumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
29th of 94
142 · median 74
Started
2024
with 7 others
Phase 2
58 of 94
11 open now
Primary completion
2026-01
later than 17 of 36 live
Registered
82nd of 94
by date
Lead sponsor
25 of 94
AstraZeneca

Among the 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung, this one is the 29th largest by enrollment, is one of 8 that started in 2024, is one of 58 in phase 2, reaches primary completion later than 17 of the 36 other live ones, and was the 82nd registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

16 of the 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 16 open studies →

About durvalumab

durvalumab: first FDA approval 2017 (IMFINZI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The purpose of this study is to assess efficacy and safety of neoadjuvant durvalumab in combination with platinum-based chemotherapy (CT) given as initial therapy after cancer diagnosis followed by either surgery and adjuvant durvalumab or chemoradiotherapy (CRT) and consolidation durvalumab given alone as further therapy in participants with resectable and borderline resectable stage IIB-IIIB NSCLC.

Read the detailed description

This will be a multicentre, Phase II, single-arm, global study assessing the efficacy and safety of neoadjuvant durvalumab and platinum-based CT, given intravenously, followed by either surgery and adjuvant durvalumab or definitive CRT and consolidation durvalumab in participants with resectable and borderline resectable stage IIB-IIIB NSCLC.

Neoadjuvant Period A:

All participants will initially receive 2 cycles of neoadjuvant durvalumab + CT (investigator's choice platinum-based) every three weeks. Participants will be assessed for resectability by a multidisciplinary team.

Neoadjuvant Period B:

Cohort 1: Participants who are deemed eligible for surgery will receive study intervention every three weeks for an additional one and up to two cycles, followed by surgery.

CRT:

Cohort 2: Participants with unresectable tumours (according to MDT re-assessment) will receive definitive CRT (6 one-week cycles) for approximately six weeks.

Both cohorts will then go on to receive durvalumab every four weeks until disease progression or recurrence or up to one year.

03

Conditions studied

  • Non-small Cell Lung Cancer

Keywords

  • Neoadjuvant
  • Durvalumab
  • Chemoradiotherapy
  • Surgery
  • Adjuvant
  • Consolidation
  • Multidisciplinary team (MDT)
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Deemed resectable or borderline resectable at baseline, confirmed by MDT evaluation at diagnosis.
  • Previously untreated and confirmed Stage IIB to select [i.e.N2] Stage IIIB by AJCC v8.
  • Nodal status confirmed with whole body FDG-PET and via endobronchial ultrasound, mediastinoscopy, or thoracoscopy.
  • Mandatory brain MRI.
  • EGFR and ALK wild-type.
  • Medically operable: adequate cardiac and lung function to undergo resection.
  • Participant must be ≥ 18 years, at the time of screening.
  • Histologically or cytologically documented NSCLC.
  • Minimum of 12 weeks.
  • Minimum body weight of 30 kg.
  • Male and female participants must be willing to use acceptable methods of .
  • Female participants of must have negative pregnancy test.

Exclusion criteria

Exclusion Criteria:

  • Unresectable NSCLC confirmed by MDT evaluation at baseline
  • Stage IIIC patients
  • Participants whose planned surgery at enrollment is a wedge resection
  • Known EGFR mutation or ALK translocation
  • Participants for surgical intervention due to comorbid conditions
  • Participants who are allergic to study intervention.
  • Participants with more than one primary tumour.
  • Known active hepatitis infection, positive antibody, or HBV core antibody (anti-HBc), at screening.
  • Female participants who are pregnant or breastfeeding.
  • Judgement by the investigator that the participant should not participate in the study.
  • Previously infected or tested positive for .
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
142 participants (actual)

Study arms

  • Experimental
    Durvalumab

    Durvalumab will be administered to the participants via intravenous infusion (IV)

    Drug: Durvalumab

Interventions

  • Participants that go on to receive surgery, will receive durvalumab for up to four cycles prior to surgery. Participants that go on to receive CRT will receive durvalumab for up to two cycles prior to CRT. All participants will receive durvalumab every four weeks until disease progression or recurrence or up to 12 months following surgery/CRT, unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met.

    Also known as: MEDI4736

06

What researchers measure

Primary outcomes

  1. Resection rate

    Resection rate is defined as the proportion of all participants who underwent definitive surgery. Participants who undergo (ie, start) surgery with the goal of complete tumour resection will be counted as meeting this endpoint.

    Time frame: At day of surgery (Within 40 days of the last dose of neoadjuvant treatment)

Secondary outcomes

  1. Resection rate

    Resection rate will be further assessed separately in participants deemed resectable at baseline and participants deemed borderline resectable at baseline.

    Time frame: At the day of surgery (within 40 days after the last dose of neoadjuvant treatment)

  2. R0, R1, R2 resection rates

    The R0, R1, and R2 resection rates (assessed separately) are defined as the proportion of resected participants with resection margins assessed as R0, R1, and R2 respectively. R0 corresponds to resection for cure or complete remission, R1 to microscopic residual tumour, R2 to macroscopic residual tumour.

    Time frame: At the day of surgery (within 40 days after the last dose of neoadjuvant treatment)

  3. Pathological complete response (pCR)

    pCR will be defined as the proportion of participants who undergo surgery and have 0% residual viable tumour cells in resected lung and lymph nodes.

    Time frame: At the day of surgery (within 40 days after the last dose of neoadjuvant treatment)

  4. Overall Survival (OS)

    OS will be defined as the time from first dose of study intervention until the date of death due to any cause.

    Time frame: From first dose of study intervention until death, withdrawal of consent, or the end of the study (approximately 3.5 years)

  5. Overall Survival (OS) rate

    The proportion of participants alive at 12 and 24 months.

    Time frame: At 12 months and 24 months

  6. Event-free survival (EFS)

    EFS is defined as the time from the first dose of study intervention to any of the following events: PD that precludes surgery, progression or recurrence of disease after surgery, PD in the absence of surgery, disease progression, recurrence, or death due to any cause.

    Time frame: From first dose of study intervention until progression of disease (PD), recurrence or death, withdrawal of consent, or the end of the study (approximately 3.5 years)

  7. Event-free survival (EFS) rate

    The proportion of participants alive and event-free at 12 and 24 months.

    Time frame: At 12 months and 24 months

  8. Progression Free Survival (PFS)

    PFS is defined as the time from the first dose of study intervention to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.-defined PD, as assessed by the investigator, or death due to any cause.

    Time frame: From first dose of study intervention until disease progression, death, withdrawal of consent, or the end of the study (approximately 3.5 years)

  9. Progression Free Survival (PFS) rate

    The proportion of participants alive without disease progression at 12 and 24 months.

    Time frame: At 12 months and 24 months

  10. Objective response rate (ORR) pre-surgery/pre-chemoradiotherapy (CRT)

    ORR is defined as the proportion of participants who have unconfirmed complete response or partial response as assessed by the investigator per RECIST 1.1.

    Time frame: From first dose of study intervention until death, surgery/start of CRT

  11. ORR during study intervention and definitive CRT

    ORR is defined as the proportion of participants who have unconfirmed complete response or partial response as assessed by the investigator per RECIST 1.1.

    Time frame: From MDT re-assessment timepoint (baseline for this endpoint) until the first tumour assessment after definitive CRT

  12. Percentage of all participants with circulating tumor DNA (ctDNA) clearance

    Circulating tumour DNA clearance (ie, cMR) will be defined as a change from detectable ctDNA to undetectable ctDNA (ctDNA concentration less than limit of detection) at specified timepoints. The percentage of all biomarker-evaluable participants with ctDNA clearance will be assessed.

    Time frame: From Cycle 1 Day 1 up to pre-surgery/CRT (within 7 to 14 days pre-surgery/CRT) [Each cycle is of 3 weeks]

  13. Number of participants with adverse events

    Safety and tolerability will be evaluated in terms of adverse events and serious adverse events.

    Time frame: From enrollment up to at least 90 days after last dose of study intervention

  14. Surgical safety: Duration of surgical procedure

    The safety of study intervention will be evaluated from start to end of surgery

    Time frame: Time from start of surgery to end of surgery

  15. Surgical safety: Length of post operative hospital stay

    The safety of study intervention will be evaluated during post operative hospital stay

    Time frame: Time from the beginning of the surgery/procedure to the discharge of hospital

  16. Surgical safety: Intended surgical approach

    Intended surgical approach at baseline (minimally invasive vs open thoracotomy).

    Time frame: At baseline

  17. Surgical safety: Actual surgical approach

    Actual surgical approach (minimally invasive vs open thoracotomy).

    Time frame: At surgery

  18. Surgical safety: Intended surgical procedure

    Intended surgical procedure (lobectomy vs bilobectomy vs sleeve resection vs pneumonectomy).

    Time frame: At baseline

  19. Surgical safety: Actual surgical procedure

    Actual surgical procedure (lobectomy vs bilobectomy vs sleeve resection vs pneumonectomy)

    Time frame: At surgery

  20. Number of participants with delayed surgery

    The safety of study intervention will be evaluated for participants with delayed surgery

    Time frame: 40 days after last dose of study intervention to surgery

  21. Surgical safety: Length of surgical delays

    The safety of study intervention will be evaluated during the length of the surgical delay

    Time frame: 40 days after last dose of study intervention to surgery

  22. Number of participants with reason of surgical delay

    The safety of study intervention will be evaluated for participants with reason of surgical delay

    Time frame: 40 days after last dose of study intervention to surgery

  23. Time from last neoadjuvant dose to surgery

    The safety of the study intervention will be evaluated from last neoadjuvant dose to surgery

    Time frame: Time from last neoadjuvant dose of study intervention to surgery

07

Study locations

49 sites
  • Research Site
    The Bronx, New York 10467, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    Charlottesville, Virginia 22908, United States
  • Research Site
    Vienna, 1130, Austria
  • Research Site
    Vienna, 1140, Austria
  • Research Site
    Kingston, Ontario K7L 2V7, Canada
  • Research Site
    Chicoutimi, Quebec G7H 5H6, Canada
  • Research Site
    Montreal, Quebec H4A 3J1, Canada
  • Research Site
    Brno, 625 00, Czechia
  • Research Site
    Olomouc, 77900, Czechia
  • Research Site
    Prague, 12808, Czechia
  • Research Site
    Prague, 150 06, Czechia
  • Research Site
    La Tronche, 38700, France
  • Research Site
    Marseille, 13008, France
  • Research Site
    Montpellier, 34295, France
  • Research Site
    Mulhouse, 68070, France
  • Research Site
    Paris, 75005, France
  • Research Site
    Pessac, 33604, France
  • Research Site
    Poitiers, 86000, France
  • Research Site
    Toulouse, 31059, France
  • Research Site
    Berlin, 13125, Germany
  • Research Site
    Cologne, 51109, Germany
  • Research Site
    Großhansdorf, 22927, Germany
  • Research Site
    Moers, 47441, Germany
  • Research Site
    Würzburg, 97074, Germany
  • Research Site
    Budapest, 1122, Hungary
  • Research Site
    Törökbálint, 2045, Hungary
  • Research Site
    Bari, 70124, Italy
  • Research Site
    Bologna, 40138, Italy
  • Research Site
    Milan, 20132, Italy
  • Research Site
    Milan, 20133, Italy
  • Research Site
    Milan, 20141, Italy
  • Research Site
    Naples, 80131, Italy
  • Research Site
    Palermo, 90127, Italy
  • Research Site
    Pavia, 27100, Italy
  • Research Site
    Peschiera del Garda, 37019, Italy
  • Research Site
    Lisbon, 1350-352, Portugal
  • Research Site
    Lisbon, 1500-650, Portugal
  • Research Site
    Barakaldo, 48903, Spain
  • Research Site
    Barcelona, 08025, Spain
  • Research Site
    L'Hospitalet de Llobregat, 08908, Spain
  • Research Site
    Madrid, 28007, Spain
  • Research Site
    Madrid, 28027, Spain
  • Research Site
    Madrid, 28046, Spain
  • Research Site
    Pamplona, 31008, Spain
  • Research Site
    Valencia, 46009, Spain
  • Research Site
    Zaragoza, 50009, Spain
  • Research Site
    Solna, 171 64, Sweden
  • Research Site
    Uppsala, SE-751 85, Sweden
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies-sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2024 to primary completion in Jan 2026, 22 months.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 22 months is below that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2023
First posted
Jun 29, 2023
StartActual
Feb 22, 2024
Primary completionActual
Jan 12, 2026
CompletionEst.
Aug 27, 2027
Last update
Sep 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05925530
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jun 29, 2023
Start date
Feb 22, 2024
Primary completion
Jan 12, 2026
Completion
Aug 27, 2027 (estimated)
Last update
Sep 9, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Durvalumab

Start the discussion